Last reviewed · How we verify

Cali Pharmaceuticals LLC — Portfolio Competitive Intelligence Brief

Cali Pharmaceuticals LLC pipeline: 0 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Naropin, 0.5% Injectable Solution Naropin, 0.5% Injectable Solution phase 3 Local anesthetic Voltage-gated sodium channels Pain management
Local anesthetic injection of CPL-01 Local anesthetic injection of CPL-01 phase 3 Local anesthetic Pain Management / Anesthesia
CPL-01 CPL-01 phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Medical University of Vienna · 2 shared drug classes
  2. University of California, San Diego · 2 shared drug classes
  3. Beijing Tiantan Hospital · 2 shared drug classes
  4. Centre Hospitalier Universitaire de Saint Etienne · 2 shared drug classes
  5. Pfizer · 2 shared drug classes
  6. Second Affiliated Hospital, School of Medicine, Zhejiang University · 2 shared drug classes
  7. Ain Shams University · 2 shared drug classes
  8. University of Colorado, Denver · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Cali Pharmaceuticals LLC:

Cite this brief

Drug Landscape (2026). Cali Pharmaceuticals LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cali-pharmaceuticals-llc. Accessed 2026-06-10.

Related